Clinical Trial Update: DAY101 vs. Standard of Care Chemotherapy in Pediatric Participants With Low-Grade Glioma Requiring First-Line Systemic Therapy (LOGGIC/FIREFLY-2) [Phase 3]

View source ↗

Summary

This clinical trial update describes a Phase 3 study (LOGGIC/FIREFLY-2) comparing DAY101 to standard-of-care chemotherapy for pediatric low-grade glioma requiri…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• DAY101 (tovorafenib)

Snippet

Sponsor: Day One Biopharmaceuticals, Inc. | Conditions: Low-grade Glioma, Rapidly Accelerated Fibrosarcoma (RAF) Altered Glioma | Phase 3 | Status: RECRUITING